International Collaborative Ovarian Neoplasm studies (1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Submission date	Recruitment status No longer recruiting	Prospectively registered		
06/04/2000		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
06/04/2000	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
31/12/2021	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Sarah Wheeler

Contact details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

abc@email.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number NCT00002477

Secondary identifying numbers

Study information

Scientific Title

International Collaborative Ovarian Neoplasm studies 1 (ICON1): A trial of adjuvant chemotherapy for early-stage ovarian cancer

Acronym

ICON1

Study objectives

Currently it is not known whether adjuvant chemotherapy is of any benefit in ovarian cancer, and all previous trials have been too small to give reliable evidence. The prognosis for early disease is much better than for advanced disease, which is known to respond to platinum-based chemotherapy, and a similar response in early disease would prolong the lives of many thousands of women each year. However, any benefit must be weighed against the toxicity associated with the treatment employed, and hence reliable evidence regarding the size of any benefit to adjuvant treatment is needed.

The aim of the study was to compare immediate with deferred chemotherapy in patients with early stage epithelial ovarian cancer

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cancer

Interventions

Immediate chemotherapy or chemotherapy deferred until indicated

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Survival time; recurrence-free survival.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1991

Completion date

21/01/2000

Eligibility

Key inclusion criteria

- 1. Chemotherapy not clearly indicated
- 2. No previous malignancy
- 3. No prior radiotherapy or chemotherapy
- 4. No contraindication to chemotherapy

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

2000

Total final enrolment

477

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1991

Date of final enrolment

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent London United Kingdom W1B 1AL +44 (0)20 7636 5422 clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

http://www.mrc.ac.uk

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications		01/11/2001		Yes	No
Other publications		15/01/2003		Yes	No
Other publications		01/11/2003		Yes	No
Other publications		01/11/2003		Yes	No
Abstract results	Long-term follow-up	20/06/2007	31/12/2021	No	No